Corneal biochemical features of patients with vernal keratoconjunctivitis

Emre, Sinan; Başer, Esin; Kaya, Metin; Zorlu, S.; Uzun, Özgür; Gülhan, Ceren

doi:10.1007/s00417-012-2089-2

Cited by 15 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the rate of developing acute hydrops is inversely proportional to age, and young age is an independent risk factor for requiring keratoplasty in keratoconus. [2122] CXL is the only modality of treatment that has been demonstrated to decrease the risk of progression and the associated morbidities. [23] CXL appears to be a safe and effective intervention in children with and without VKC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and efficacy of corneal cross-linking in pediatric patients with keratoconus and vernal keratoconjunctivitis

Alrobaian

Elsayed

Alotaibi

et al. 2019

Middle East Afr J Ophthalmol

View full text Add to dashboard Cite

PURPOSE:The purpose of the study is to determine the safety and efficacy of corneal collagen cross-linking for keratoconus in pediatric patients with and without vernal keratoconjunctivitis (VKC).METHODS:This is a retrospective analysis of 89 eyes of 58 patients <18 years of age that underwent corneal collagen cross-linking for progressive keratoconus; inclusion criteria included a minimum of 2-year follow-up after cross-linking. The main outcomes measures included keratometry, pachymetry, vision, and complications following epithelial-off cross-linking with the Dresden protocol.RESULTS:VKC patients were more likely to be male; 81.6% of the non-VKC patients and 96.3% of VKC patients were male (P = 0.038). Comparing pretreatment to the 2-year follow-up, there was no statistically significant change in the mean steep or flat keratometry, corneal thickness, and uncorrected visual acuity or best spectacle-corrected visual acuity in either group. There were no statistically significant differences in the mean visual, keratometric, or adverse event outcomes between the two groups. The proportion exhibiting progression of ectasia at 2 years was 18.5% in the VKC group and 16.7% in the non-VKC group (P = 0.83).CONCLUSIONS:Cross-linking appears to be as safe and effective in pediatric patients with vernal keratoconjunctivits as in those without, with similar outcomes, adverse events, and progression of keratoconus after treatment. The proportion of patients exhibiting progression appears to be higher in pediatric patients than adults, and there is an association between male sex and diagnosis of VKC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Keratoconus that manifests in early childhood is commonly associated with vernal keratoconjunctivitis (VKC). [18192021] It is possibly related to frequent eye rubbing and chronic corneal exposure to inflammatory mediators and cytokines. The safety and efficacy of CXL has not been validated in pediatric patients with VKC and keratoconus.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of corneal cross-linking in pediatric patients with keratoconus and vernal keratoconjunctivitis

Alrobaian

Elsayed

Alotaibi

et al. 2019

Middle East Afr J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Diagnosis is based on symptoms and signs including itching, photophobia, sticky mucous discharge, giant papillae on the upper tarsal conjunctiva or at the limbus, Trantas' dots, superficial keratopathy, and corneal shield ulcer [1][2][3]. Recent studies have documented various alterations of cornea, conjunctiva and tear film in VKC patients [4][5][6]. The disease was bilateral in 96.7% of the cases; all unilateral cases involved the tarsal form of VKC [7,8].…”

mentioning

confidence: 99%

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Keklíkçí¹,

Dursun²,

Cingü³

2014

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Vernal keratoconjunctivitis (VKC) is a chronic, bilateral inflammation of the conjunctiva that mostly affects children and young adult males. Management of VKC is primarily aimed at reducing symptoms and preventing serious vision threatening sequelae. Objectives. To assess the efficacy of topical cyclosporine A (CsA) 0.05% on the signs and symtomps in the management of VKC. Material and Methods. This is a placebo-controlled, randomized prospective study. Sixty-two patients with VKC were included in this study. Patients were randomly assigned (1 : 1) to treatment with topical 0.05% CsA eyedrops or a placebo (artificial tears) for a period of 4 weeks, 4 times daily. Ocular signs and symptoms were in all patients scored at entry and at the end of 4 weeks. Results. When pre-treatment mean signs and symptoms scores were compared in both groups, there was no significant difference (p > 0.05). However, mean post-treatment scores as regards signs and symptoms were found to be lower in cyclosporine group than those in placebo group (p < 0.001). No side effects of the treatment with CsA 0.05% eyedrops were observed. Conclusions. It was found that topical CsA 0.05% eyedrops were safe and effective in the treatment of patients with VKC (Adv Clin Exp Med 2014, 23, 3, 455-461).

show abstract

“…Chronic and severe, VKC typically manifests in children and adolescents in the hot, dry climates of equatorial regions, predominating in boys with a 3:1 ratio. Approximately 50% of VKC patients have histories of atopy, for example, asthma, allergic rhinitis, or eczema [De Smedt et al 2013; Emre et al 2013; Leonardi, 2013; Gomes, 2014; Miraldi Utz and Kaufman, 2014]. The diagnostic features are tarsal papillae and limbal gelatinous infiltrates with exacerbation by allergenic re-exposure and/or sunlight, wind, and dust [Leonardi, 2013; Gomes, 2014; Miraldi Utz and Kaufman, 2014].…”

Section: The Pathognomonic Symptom With Clinical Consequencesmentioning

confidence: 99%

Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management

Ackerman

Smith

Gomes

2016

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Allergic conjunctivitis is one of the most common allergic conditions worldwide. Its incidence is increasing due to changing climate, pollution, increased pollen loads, and the subject's heightened immunological sensitivity in response to these environmental changes. The pathophysiology predominantly involves immunoglobulin E-related mast-cell activation, with release of histamine and other mediators contributing to the propagation of the response by calling in other immune cells and further inflammation. This article presents the evolution of ocular allergy treatments, from vasoconstrictors, to antihistamines and mastcell stabilizers, to the dual-acting agents, as well as corticosteroid and immunomodulatory options. Future targets for allergy treatment are also discussed.

show abstract

Corneal biochemical features of patients with vernal keratoconjunctivitis

Abstract: The mean CRF and IOPg values of patients with VKC were lower than those of controls. According to the results of our study, one can conclude that corneal biomechanical property, CRF, could be different in VKC patients compared to normals.

Cited by 15 publications

References 23 publications

Safety and efficacy of corneal cross-linking in pediatric patients with keratoconus and vernal keratoconjunctivitis

Safety and efficacy of corneal cross-linking in pediatric patients with keratoconus and vernal keratoconjunctivitis

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management

Contact Info

Product

Resources

About